New Insights into Weight Loss Therapies: GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide
Published: May 16, 2026 | Source: Obesity (Silver Spring, Md.) (2025) | Category: GLP-1 receptor agonists, dual agonists, retatrutide
Overview
A recent study published in Obesity offers a comprehensive comparison of the efficacy and safety profiles of GLP-1 receptor agonists (GLP-1RAs), dual agonists, and retatrutide for weight loss among adults with overweight or obesity. The findings suggest that while these therapies are effective, they come with varying levels of risk and benefits depending on patient characteristics.
Study Background
Previous research has highlighted the potential of GLP-1 receptor agonists in aiding weight management, but there was a need to understand how newer agents like dual agonists and retatrutide compare. This study aimed to fill that gap by conducting a Bayesian network meta-analysis (NMA) to evaluate these treatments comprehensively.
What the Research Found
The analysis included 19 randomized controlled trials involving over 29,500 participants with BMI ≥ 25 kg/m². The results showed that retatrutide and dual agonists achieved a mean weight loss of -11.0 kg, surpassing GLP-1RAs at -9.0 kg. Retatrutide was particularly effective in achieving ≥ 15% weight loss, with an odds ratio (OR) of 54.6 compared to GLP-1RAs and dual agonists at ORs of 16.4 and 9.0 respectively.
However, retatrutide also had the highest adverse event risk among the three types of treatments. The study further noted that type 2 diabetes mellitus (T2DM) reduced weight loss efficacy for both GLP-1RAs and dual agonists by approximately 5 kg on average. Additionally, female-dominant or high-BMI cohorts showed enhanced outcomes with these therapies.
What This Means for Peptide Users
For patients considering peptide therapy for weight management, the study provides valuable insights into the comparative benefits and risks of different treatment options. Retatrutide offers superior efficacy but comes with a higher risk of adverse events, making it less suitable for all patient profiles. Dual agonists appear to offer a balanced approach between effectiveness and safety.
Limitations and Caveats
The study acknowledges several limitations, including potential publication bias and heterogeneity among the included trials. The impact of T2DM on treatment efficacy also complicates the interpretation of results, suggesting that personalized treatment selection based on patient characteristics is crucial.
How This Compares to Previous Research
While previous studies have highlighted the effectiveness of GLP-1RAs for weight loss, this study provides a more nuanced comparison by including dual agonists and retatrutide. The findings align with earlier research in terms of efficacy but offer new insights into safety profiles and patient-specific outcomes.
Our Analysis
PeptideVault's critical assessment suggests that while the study offers valuable comparative data on GLP-1RAs, dual agonists, and retatrutide, its limitations must be considered. The high adverse event risk associated with retatrutide underscores the importance of personalized treatment approaches in clinical practice.
Key Takeaways
- Retatrutide is highly effective for weight loss but carries a higher risk of adverse events.
- Dual agonists provide an optimal balance between efficacy and safety, making them suitable for broader patient profiles.
- Personalized treatment selection based on individual characteristics such as T2DM status and BMI is recommended.
Original Source
Citation: Sinha Binayak, Ghosal Samit (2025). Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.. Obesity (Silver Spring, Md.). DOI: 10.1002/oby.24360
Access: https://pubmed.ncbi.nlm.nih.gov/40685589/
---
This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.